APA (7th ed.) Citation

HE, E., RH, S., YA, M., AA, G. E. D., K, M., AE, E., . . . H, N. A. (2025). Dipeptidyl peptidase-4 enzyme inhibition and its impacts on hepatic preneoplasia: A new avenue for liver cancer management. Frontiers in pharmacology, 16, 1559303. https://doi.org/10.3389/fphar.2025.1559303

Chicago Style (17th ed.) Citation

HE, Eitah, Sayed RH, Maklad YA, Gamal El Din AA, Mahmoud K, El-Sahar AE, Alhejely A, Abdulbaqi AA, and Naeim Attia H. "Dipeptidyl Peptidase-4 Enzyme Inhibition and Its Impacts on Hepatic Preneoplasia: A New Avenue for Liver Cancer Management." Frontiers in Pharmacology 16 (2025): 1559303. https://doi.org/10.3389/fphar.2025.1559303.

MLA (9th ed.) Citation

HE, Eitah, et al. "Dipeptidyl Peptidase-4 Enzyme Inhibition and Its Impacts on Hepatic Preneoplasia: A New Avenue for Liver Cancer Management." Frontiers in Pharmacology, vol. 16, 2025, p. 1559303, https://doi.org/10.3389/fphar.2025.1559303.